Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy

Trans Assoc Am Physicians. 1993:106:33-41.

Authors

B F Haynes¹, Y Yasutomi, J V Torres, M B Gardner, A J Langlios, D P Bolognesi, T J Matthews, R M Scearce, D M Jones, M A Moody, et al.

Affiliation

¹ Department of Medicine, Duke University Arthritis Center, Durham, NC.

PMID: 8036743

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

AIDS Vaccines / immunology
AIDS Vaccines / isolation & purification
AIDS Vaccines / pharmacology*
Amino Acid Sequence
Animals
HIV Antibodies / biosynthesis*
HIV Envelope Protein gp120 / genetics
HIV Envelope Protein gp120 / immunology
HIV Infections / prevention & control
HLA Antigens
Histocompatibility Antigens Class I
Humans
Macaca mulatta
Molecular Sequence Data
Neutralization Tests
Peptide Fragments / genetics
Peptide Fragments / immunology
Peptides / chemical synthesis
Peptides / genetics
Peptides / immunology*
Simian Immunodeficiency Virus / genetics
Simian Immunodeficiency Virus / immunology
T-Lymphocytes, Cytotoxic / immunology*

Substances

AIDS Vaccines
HIV Antibodies
HIV Envelope Protein gp120
HIV envelope protein gp120 (305-321)
HLA Antigens
Histocompatibility Antigens Class I
Peptide Fragments
Peptides

Grants and funding